Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 18377662
Bhattacharya R, et al. (2008) Src homology 2 (SH2) domain containing protein tyrosine phosphatase-1 (SHP-1) dephosphorylates VEGF Receptor-2 and attenuates endothelial DNA synthesis, but not migration*. J Mol Signal 3, 8 18377662
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

Y536-p - SHP-1 (human)
Modsite: QkGQEsEyGNItyPP SwissProt Entrez-Gene
Orthologous residues
SHP‑1 (human): Y536‑p, SHP‑1 iso2 (human): Y497‑p, SHP‑1 iso3 (human): Y538‑p, SHP‑1 iso4 (human): Y536‑p, SHP‑1 (mouse): Y536‑p, SHP‑1 (rat): Y538‑p
Characterization
Methods used to characterize site in vivo mutation of modification site
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced

Y951-p - VEGFR2 (human)
Modsite: RFRQGKDyVGAIPVD SwissProt Entrez-Gene
Orthologous residues
VEGFR2 (human): Y951‑p, VEGFR2 (mouse): Y949‑p, VEGFR2 (rat): Y947‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
siRNA VEGF SHP-1 (human) no effect upon treatment-induced increase
PP2 VEGF no effect upon treatment-induced increase
PP3 VEGF no effect upon treatment-induced increase

Y996-p - VEGFR2 (human)
Modsite: EEAPEDLyKDFLTLE SwissProt Entrez-Gene
Orthologous residues
VEGFR2 (human): Y996‑p, VEGFR2 (mouse): Y994‑p, VEGFR2 (rat): Y992‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE SHP-1 (human) pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, siRNA inhibition of enzyme, phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
siRNA VEGF SHP-1 (human) augment treatment-induced increase
PP2 VEGF augment treatment-induced increase
PP3 VEGF no effect upon treatment-induced increase

Y1059-p - VEGFR2 (human)
Modsite: DIykDPDyVRKGDAR SwissProt Entrez-Gene
Orthologous residues
VEGFR2 (human): Y1059‑p, VEGFR2 (mouse): Y1057‑p, VEGFR2 (rat): Y1055‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE SHP-1 (human) pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, siRNA inhibition of enzyme, phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
siRNA VEGF SHP-1 (human) augment treatment-induced increase
PP2 VEGF augment treatment-induced increase
PP3 VEGF no effect upon treatment-induced increase

Y1175-p - VEGFR2 (human)
Modsite: AQQDGKDyIVLPISE SwissProt Entrez-Gene
Orthologous residues
VEGFR2 (human): Y1175‑p, VEGFR2 (mouse): Y1173‑p, VEGFR2 (rat): Y1171‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE SHP-1 (human) pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, siRNA inhibition of enzyme, phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
siRNA VEGF SHP-1 (human) augment treatment-induced increase
PP2 VEGF augment treatment-induced increase
PP3 VEGF no effect upon treatment-induced increase